These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

547 related articles for article (PubMed ID: 19509501)

  • 21. PDE5 inhibitors beyond erectile dysfunction.
    Sandner P; Hütter J; Tinel H; Ziegelbauer K; Bischoff E
    Int J Impot Res; 2007; 19(6):533-43. PubMed ID: 17625575
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Management of erectile dysfunction after radical prostatectomy.
    Hall MC
    Semin Urol Oncol; 1995 Aug; 13(3):215-23. PubMed ID: 8521135
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Daily administration of phosphodiesterase type 5 inhibitors for urological and nonurological indications.
    Bella AJ; Deyoung LX; Al-Numi M; Brock GB
    Eur Urol; 2007 Oct; 52(4):990-1005. PubMed ID: 17646047
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Erectile dysfunction therapy in special populations and applications: coronary artery disease.
    DeBusk RF
    Am J Cardiol; 2005 Dec; 96(12B):62M-66M. PubMed ID: 16387570
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The impact of the use of PDE5 inhibitors for erectile dysfunction on the lives of Australian men.
    Matic H; McCabe MP
    Int J Impot Res; 2007; 19(4):418-23. PubMed ID: 17538638
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Novel indications for phosphodiesterase type 5 inhibitors].
    Rosenkranz S; Caglayan E; Erdmann E
    Med Klin (Munich); 2007 Aug; 102(8):617-30. PubMed ID: 17694282
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacological therapy for the treatment of sexual dysfunction--are we there yet?
    Costabile RA
    J Urol; 2008 Mar; 179(3):819-20. PubMed ID: 18221964
    [No Abstract]   [Full Text] [Related]  

  • 28. The effect of erectile function on the use of phosphodiesterase-5 inhibitors after radical prostatectomy in Japanese and U.S. men.
    Namiki S; Kwan L; Kagawa-Singer M; Arai Y; Litwin MS
    Urology; 2008 May; 71(5):901-5. PubMed ID: 18374396
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recovery of sexual function after prostate cancer treatment.
    Donatucci CF; Greenfield JM
    Curr Opin Urol; 2006 Nov; 16(6):444-8. PubMed ID: 17053525
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Survivorship beyond convalescence: 48-month quality-of-life outcomes after treatment for localized prostate cancer.
    Gore JL; Kwan L; Lee SP; Reiter RE; Litwin MS
    J Natl Cancer Inst; 2009 Jun; 101(12):888-92. PubMed ID: 19509365
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Intraurethrally applicated alprostadil for the treatment of organic erectile dysfunction in practice: a multicenter clinical monitoring study (noninterventional investigation)].
    Potempal AJ; Potempa DM; Görlich HD; Stolpmann RM
    Arzneimittelforschung; 2007; 57(6):299-308. PubMed ID: 17688074
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Erectile dysfunction after radiotherapy for prostate cancer.
    Mendenhall WM; Henderson RH; Indelicato DJ; Keole SR; Mendenhall NP
    Am J Clin Oncol; 2009 Aug; 32(4):443-7. PubMed ID: 19657239
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gene therapy and erectile dysfunction: the current status.
    Lau DH; Kommu SS; Siddiqui EJ; Thompson CS; Morgan RJ; Mikhailidis DP; Mumtaz FH
    Asian J Androl; 2007 Jan; 9(1):8-15. PubMed ID: 16888683
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A model for managing erectile dysfunction following prostate cancer treatment.
    Park DL; Aron M; Rewcastle JC; Boyd SD; Gill IS
    Curr Opin Urol; 2013 Mar; 23(2):129-34. PubMed ID: 23321631
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Urinary and sexual disorders following localised prostate cancer management].
    Haab F; Beley S; Cornu JN; Culine S; Cussenot O; Hennequin C
    Bull Cancer; 2010 Dec; 97(12):1537-49. PubMed ID: 21220229
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Phosphodiesterase type 5 inhibitors in postprostatectomy erectile dysfunction: a critical analysis of the basic science rationale and clinical application.
    Hatzimouratidis K; Burnett AL; Hatzichristou D; McCullough AR; Montorsi F; Mulhall JP
    Eur Urol; 2009 Feb; 55(2):334-47. PubMed ID: 18986755
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular mechanisms that could contribute to prolonged effectiveness of PDE5 inhibitors to improve erectile function.
    Francis SH; Morris GZ; Corbin JD
    Int J Impot Res; 2008; 20(4):333-42. PubMed ID: 18418391
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sexual rehabilitation and cancer survivorship: a state of art review of current literature and management strategies in male sexual dysfunction among prostate cancer survivors.
    Chung E; Brock G
    J Sex Med; 2013 Feb; 10 Suppl 1():102-11. PubMed ID: 23387915
    [TBL] [Abstract][Full Text] [Related]  

  • 39. What happened? Sexual consequences of prostate cancer and its treatment.
    Katz A
    Can Fam Physician; 2005 Jul; 51(7):977-82. PubMed ID: 16060176
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Current safety and tolerability issues in men with erectile dysfunction receiving PDE5 inhibitors.
    Hellstrom WJ
    Int J Clin Pract; 2007 Sep; 61(9):1547-54. PubMed ID: 17655683
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.